Biogen Raises Profit Guidance Amid Leqembi Growth and MS Sales Decline

Profit Guidance Increase:
Biogen has raised its full-year profit guidance, expecting adjusted EPS to range from $16.10 to $16.60, up from previous estimates.

Leqembi Performance:
Despite a modest quarter for Leqembi, Biogen's Alzheimer's drug, it has shown signs of gaining traction, contributing to the company's improved earnings.

Multiple Sclerosis Sales Decline:
Biogen has experienced a downturn in multiple sclerosis drug sales, but this has been offset by new treatments and cost-cutting measures.

Earnings Report:
Biogen's earnings have topped estimates, leading to a boost in the company's stock price.

Strategic Moves:
The company's focus on new treatments and cost-cutting measures has helped mitigate the decline in MS sales, contributing to the overall positive earnings report.